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Summary
 
To determine the effect of a physiologically relevant elevation in the plasma concentrations of
epinephrine on the activation of the hemostatic mechanism during endotoxemia, 17 healthy
men were studied after intravenous injection of lipopolysaccharide (LPS, 2 ng/kg), while  receiving
a continuous infusion of epinephrine (30 ng/kg/min) started either 3 h (
 
n
 
 
 
5
 
 5) or 24 h (
 
n
 
 
 
5
 
 6)
before LPS injection, or an infusion of normal saline (
 
n
 
 
 
5
 
 6). Activation of the coagulation sys-
tem (plasma concentrations of thrombin–antithrombin III complexes and prothrombin frag-
ment F1
 
1
 
2) was significantly attenuated in the groups treated with epinephrine when com-
pared with subjects injected with LPS only (
 
P
 
 
 
,
 
0.05). Epinephrine enhanced LPS-induced
activation of fibrinolysis (plasma levels of tissue-type plasminogen activator and plasmin-
 
a
 
2
 
–antiplas-
min complexes; 
 
P
 
 
 
,
 
0.05), but did not influence inhibition of fibrinolysis (plasminogen activa-
tor inhibitor type I). In subjects infused with epinephrine, the ratio of maximal activation of
coagulation and maximal activation of fibrinolysis was reduced by 
 
.
 
50%. Hence, epinephrine
exerts antithrombotic effects during endotoxemia by concurrent inhibition of coagulation, and
stimulation of fibrinolysis. Epinephrine, whether endogenously produced or administered as a
component of treatment, may limit the development of disseminated intravascular coagulation
during systemic infection.
 
A
 
systemic inflammatory response syndrome (SIRS) is
frequently associated with disseminated intravascular
coagulation, a serious complication that significantly con-
tributes to organ injury and mortality (1). Enhanced release of
epinephrine is part of the early host response to acute sys-
temic infection and inflammation (2, 3). Although the role
of epinephrine changes in substrate and energy metabolism,
and cardiovascular control during SIRS has been widely rec-
ognized (2–4), knowledge of the in vivo effects of this cat-
echolamine on activation of the hemostatic mechanism is
limited.
It is conceivable that epinephrine influences coagulant and
fibrinolytic pathways during SIRS for several reasons. Epi-
nephrine has  been reported to stimulate the release of tis-
sue-type plasminogen activator (tPA) in humans in vivo (5,
6). Further, expression of tissue factor, the essential media-
tor of coagulation activation during SIRS (7, 8), can be in-
hibited in vitro by agents that elevate cellular cAMP (9, 10).
Since 
 
b
 
 adrenergic stimulation results in an increase in cel-
lular cAMP concentrations (11, 12), it can be anticipated that
epinephrine is able to influence coagulation. Knowledge of
the hemostatic effect of epinephrine is important not only for
the understanding of influences of endogenous adrenergic
responses on the regulation of coagulation during SIRS, but
also for the therapeutic use of catecholamines in patients with
septic shock. Therefore, in the present study we sought to
determine the effect of a constant intravenous epinephrine
infusion on the activation of the hemostatic mechanism
during low dose endotoxemia in normal humans.
 
Materials and Methods
 
Study Design and Subjects.
 
This study was performed simulta-
neously with an investigation determining the effect of epineph-
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rine on LPS-induced cytokine release (13). The study was ap-
proved by the Institutional Review Board, and written informed
consent was obtained from all subjects before enrollment in the
study. 19 male subjects, aged  28 
 
6
 
 1 (mean 
 
6
 
 SE) yr, were ad-
mitted to the Adult Clinical Research Center of the New York
Hospital-Cornell University Medical Center for 4 d (day 0 to day
3). On day 1, 8 subjects were started on a constant intravenous in-
fusion of epinephrine (30 ng/kg/min; Parke-Davis, Morris Plains,
NJ), starting at 9:00 AM. On day 2, at 9:00 AM, 6 of these 8 sub-
jects, were intravenously injected with a single dose of LPS (Na-
tional Reference Endotoxin, 
 
Escherichia coli
 
 0113 (lot EC-5), gen-
erously provided by Dr. H.D. Hochstein (Bureau of Biologics,
Food and Drug Administration, Bethesda, MD) at a dose of 2 ng/
kg body weight (EPI-24 group). The infusion of epinephrine was
continued until 6 h after LPS administration (3:00 PM). The 11
other subjects were randomized on day 2 to receive either a con-
stant intravenous infusion of epinephrine (30 ng/kg/min; 
 
n
 
 
 
5
 
 5),
starting at 6:00 AM (3 h before LPS administration) and contin-
ued until 3:00 PM (EPI-3 group), or an equivalent volume of
normal saline (
 
n
 
 
 
5
 
 6) (LPS group). These subjects also were in-
jected with LPS (2 ng/kg) at 9:00 AM. Epinephrine was freshly
prepared in normal saline every 8 h. 3 h before the administration
of LPS a radial arterial catheter was placed in all subjects for blood
sampling.
 
Sampling and Assays.
 
On day 1, venous blood was obtained
before the start of infusion with epinephrine (
 
t
 
 
 
5 
 
0 h), and at 1, 2, 4,
and 8 h thereafter. On day 2, arterial blood was obtained at 6:00
AM (i.e., directly before the start of the infusion of epinephrine
in the EPI-3 group or the start of saline infusion in the LPS
group) (
 
t
 
 
 
5
 
 
 
2
 
3 h), directly before the injection of LPS (
 
t
 
 
 
5
 
 0 h),
and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 24 h thereafter. All blood
samples were centrifuged at 4
 
8
 
C for 20 min at 1,600 
 
g
 
 and plasma
was stored at 
 
2
 
70
 
8
 
C until assayed.
Activation of the coagulation system was determined in cit-
rated plasma by measurements of prothrombin fragment F1
 
1
 
2
and thrombin–antithrombin III (TAT) complexes (ELISAs; Beh-
ringwerke AG, Marburg, Germany). Activation of fibrinolysis
was determined in citrated plasma by measurements of tPA anti-
gen and plasminogen activator inhibitor type I (PAI-1) antigen
(ELISAs; Innogenetics, Nijmegen, The Netherlands), PAI-1 activity
by amidolytic assay (Chromogenix, Mölndal, Sweden), and plas-
min-
 
a
 
2
 
–antiplasmin (PAP) complexes (8). Soluble E-selectin
levels were measured in K
 
2
 
-EDTA anticoagulated plasma by
ELISA (14).
 
Statistical Analysis.
 
All values are given as means 
 
6
 
 SEM.
Differences within groups were analyzed by one-way analysis of
variance. Differences between groups were analyzed by two-way
analysis of variance (interaction treatment and time). Two sample
comparisons were performed by Wilcoxon test. 
 
P
 
 
 
,
 
0.05 was
considered to represent a statistically significant difference.
 
Results
 
Activation of Coagulation.
 
Infusion of epinephrine only
(day 1) did not influence the plasma concentrations of F1
 
1
 
2
or TAT complexes (data not shown). Injection of LPS in-
duced transient rises in plasma F1
 
1
 
2 and TAT complexes,
peaking after 4 h (4.61 
 
6
 
 1.03 nmol/l and 31.9 
 
6
 
 4.7 ng/ml,
respectively; both 
 
P
 
 
 
,
 
0.05 versus time). Both EPI-3 and
EPI-24 strongly attenuated LPS-induced coagulation acti-
vation (Fig. 1). In the EPI-3 group, peak concentrations of
F1
 
1
 
2 and TAT complexes were 1.88 
 
6
 
 0.34 nmol/l and
16.5 
 
6
 
 5.6 ng/ml, respectively, in the EPI-24 group, 2.25 
 
6
Figure 1. Epinephrine inhibits LPS-induced coagulation activation.
Mean (6 SE) plasma concentrations of prothrombin fragment F112 and
TAT complexes  after intravenous injection of LPS (2 ng/kg, lot EC-5) at
t 5 0. LPS 5 subjects injected with LPS only (n 5 6); EPI-3 5 subjects
infused with epinephrine (30 ng/kg/min) from t 5 23 h to 6 h (n 5 5);
EPI-24 5 subjects infused with epinephrine (30 ng/kg/min) from t 5
224 h to 6 h (n 5 6). Both EPI-3 and EPI-24 attenuated LPS-induced
increases in F112 and TAT complexes (P ,0.05 versus LPS only).
 
Table 1.
 
Effect of Epinephrine on Fibrinolysis
 
Time
tPA
antigen
PAP
complexes
PAI-1
antigen
PAI-1
activity
 
h ng/ml nmol/l ng/ml ng/ml
 
0 3.5 
 
6
 
 0.6 5.9 
 
6
 
 1.1 7.1 
 
6
 
 1.0 4.0 
 
6
 
 0.8
1 11.6 
 
6
 
 1.8 14.4 
 
6
 
 2.3 7.3 
 
6
 
 0.8 4.4 
 
6
 
 0.9
2 6.1 
 
6
 
 1.7 9.9 
 
6
 
 0.9 8.6 
 
6
 
 0.6 4.9 
 
6
 
 0.8
4 4.6 
 
6
 
 1.3 8.1 
 
6
 
 0.8 5.6 
 
6
 
 0.8 5.0 
 
6
 
 0.8
8 3.3 6 0.6 7.5 6 1.0 7.9 6 0.9 7.1 6 1.0
21 3.6 6 0.6 6.3 6 1.1 10.6 6 1.3 4.5 6 0.7
24 3.2 6 0.6 6.1 6 0.9 10.6 6 1.4 5.3 6 0.5
P vs. time P ,0.05 P ,0.05 P ,0.05 NS
Data are mean 6 SE of eight subjects receiving a continuous 24-h in-
travenous infusion of epinephrine (30 ng/kg/min) starting at t 5 0. NS,
nonsignificant.1145 van der Poll et al. Brief Definitive Report
0.55 nmol/l and 14.6 6 4.4 ng/ml, respectively (all P ,0.05
versus LPS only).
Activation of Fibrinolysis. Infusion of epinephrine only
(day 1) modestly stimulated fibrinolysis, as reflected by
transient rises in the plasma concentrations of tPA and PAP
complexes. Epinephrine also caused a relatively late in-
crease in the plasma levels of PAI-1 antigen (Table 1).
Administration of LPS resulted in a marked activation of
fibrinolysis, followed by a strong inhibition coinciding with
maximal coagulation activation (Fig. 2). Peak levels of in-
dexes of fibrinolytic activation were found after 1.5 to 2 h,
i.e., before maximal coagulation activation: tPA antigen
(32.1  6 2.0 ng/ml) and PAP complexes (33.9 6 4.5 nmol/l)
(both P ,0.05 versus time). Peak levels of indexes of inhi-
bition of fibrinolysis were found thereafter, i.e., after 4 h:
PAI-1 antigen (140.7 6 9.9 ng/ml) and PAI activity (42.0 6
3.2 ng/ml) (both P ,0.05 versus time). Both EPI-3 and
EPI-24 enhanced LPS-induced activation of fibrinolysis
(Fig. 2). In the EPI-3 group, peak levels of tPA antigen and
PAP complexes were 47.8 6 2.6 ng/ml and 50.2 6 5.4
nmol/l (both P ,0.05 versus LPS only), respectively. In
the EPI-24 group, these levels were 44.2 6 2.7 ng/ml and
50.6 6 7.3 nmol/l (both P ,0.05 versus LPS only), re-
spectively. By contrast, neither EPI-3 nor EPI-24 influ-
enced inhibition of fibrinolysis after injection of LPS, as re-
flected by unchanged increases in the plasma levels of PAI-1
antigen and PAI activity in the three study groups (Fig. 2).
Ratio of Coagulation and Fibrinolysis. Since epinephrine ap-
peared to inhibit coagulation and enhance fibrinolysis, we
were interested in the effect of epinephrine on the balance
between coagulation and fibrinolysis. For this purpose we
calculated the ratio of the peak plasma levels of TAT com-
plexes and PAP complexes. Both EPI-3 and EPI-24 reduced
this ratio to ,50% of the ratio found after administration of
LPS only (P ,0.05; Table 2).
Soluble E-Selectin. LPS injection elicited a sustained in-
crease in the plasma levels of soluble E-selectin (P ,0.05
Figure 2. Epinephrine enhances LPS-induced fibrinolytic activation,
while not influencing inhibition of fibrinolysis. Mean (6 SE) plasma con-
centrations of tPA antigen, PAP complexes, PAI-1 antigen, and activity
after intravenous injection of LPS (2 ng/kg, lot EC-5) at t 5 0. LPS 5
subjects injected with LPS only (n 5 6); EPI-3 5 subjects infused with
epinephrine (30 ng/kg/min) from t 523 h to 6 h (n 5 5); EPI-24 5
subjects infused with epinephrine (30 ng/kg/min) from t 5 224 h to 6 h
(n 5 6).  EPI-3 and EPI-24 enhanced LPS-induced increases in tPA and
PAP complexes (P ,0.05 versus LPS only), while not significantly chang-
ing PAI-1 antigen or activity.
Table 2. The Effect of Epinephrine on the Coagulation/
Fibrinolysis Balance
Subject LPS EPI-3 EPI-24
1 0.61 0.69 0.54
2 0.83 0.49 0.51
3 1.17 0.18 0.14
4 0.89 0.42 0.64
5 1.07 0.38 0.29
6 1.08 2 0.25
Mean 6 SE 0.94 6 0.08 0.43 6 0.08* 0.40 6 0.08*
Data are ratios of peak plasma levels of TAT complexes and PAP com-
plexes, reflecting activation of coagulation and fibrinolysis respectively.
LPS, subjects injected with LPS only; EPI-3, subjects infused with epi-
nephrine (30 ng/kg/min) from t 5 23 h to 6 h; EPI-24, subjects in-
fused with epinephrine (30 ng/kg/min) from t 5 224 h to 6 h.
*P ,0.05 versus LPS.1146 Epinephrine Exerts Anticoagulant Effects during Endotoxemia
versus time), which was attenuated by EPI-3 and EPI-24
(P ,0.05 versus LPS only; Fig. 3). Soluble E-selectin levels
were not influenced by infusion of epinephrine only (day 1)
(data not shown).
Discussion
This study demonstrates for the first time that epineph-
rine exerts a strong anticoagulant effect during endotox-
emia. Epinephrine attenuated activation of the coagulation
system induced by intravenous injection of LPS, and con-
currently enhanced activation of the fibrinolytic system.
The anticoagulant properties of epinephrine were further
demonstrated by a .50% reduction in the ratio of maximal
coagulation activation and maximal fibrinolytic activation.
These  effects of epinephrine on the hemostatic mechanism
were found at physiologically relevant plasma concentra-
tions (1,000–1,200 pg/ml) (13). Indeed, the infusion of
epinephrine sought to mimic two clinically relevant situa-
tions, i.e. epinephrine concentrations achieved were in the
same range as those found in patients with SIRS, and the
rate and dose at which epinephrine was infused resembled
the rate and dose at which the hormone is started as part of
supportive treatment of SIRS (13). 
We chose to start the infusion of epinephrine at 3 or 24 h
before LPS administration because in vitro studies had sug-
gested that the effect of epinephrine on intracellular cAMP
levels is dependent on the duration of exposure of cells to
this hormone (12). Thus, incubation of mononuclear cells
with epinephrine for 2 h increased cellular cAMP concen-
trations, while incubation for 24 h was associated with a
decrease in cAMP levels (12). cAMP plays a pivotal role in
many inflammatory reactions, including expression of tissue
factor on mononuclear cells (9, 10), a process mediating ac-
tivation of the common pathway of the coagulation system
during SIRS (1, 7, 8). We hypothesized that b adrenergic
stimulation would inhibit LPS-induced tissue factor expres-
sion as a consequence of a direct increase in cAMP levels.
Considering the biphasic effect of epinephrine on cellular
cAMP concentrations in vitro (12), we considered it im-
portant to determine the influence of epinephrine infusions
of various durations on the coagulation system. However,
both EPI-3 and EPI-24 inhibited LPS-induced coagulation
activation. The release of TNF, a cytokine of which the pro-
duction is negatively regulated by cAMP (12, 15), was also
reduced in both the EPI-3 and EPI-24 groups (13), albeit
to a lesser extent in the latter group. However, the circulat-
ing levels of IL-10, the production of which is positively
regulated by cAMP (16), were increased only in the EPI-3
group (13). Hence, the duration of the effect of epineph-
rine may vary from response to response, i.e., brief (IL-10),
intermediate (TNF), or long (coagulation). We did not di-
rectly measure cAMP concentrations within circulating
mononuclear cells. It should be noted, however, that we
were previously unable to demonstrate enhanced tissue fac-
tor expression on circulating monocytes in this model of
low grade endotoxemia (17), suggesting that cells not
present in the circulation are involved in initiation of coag-
ulation. Nonetheless, our data do not firmly establish the
duration of the in vivo effect of epinephrine on intracellu-
lar cAMP, or the mechanism underlying the variable dura-
tion of epinephrine effects considered to be mediated by
elevated cAMP levels.
It can be argued that decreased TNF and increased IL-10
concentrations (13) might have contributed to the antico-
agulant effect of epinephrine, since TNF stimulates and IL-10
inhibits tissue factor expression in vitro (18, 19). However,
it is unlikely that the inhibition of coagulation activation by
epinephrine was mediated via an effect on the cytokine sys-
tem. Indeed, TNF is not necessary for activation of coagu-
lation during low grade endotoxemia (20), and IL-10 levels
were unaltered in the EPI-24 group, whereas this group
showed a similar inhibition of coagulation as the EPI-3
group (13). Further, neither epinephrine infusion influenced
LPS-induced release of IL-6 (13), a cytokine that appears to
play an important role in LPS-induced coagulation activa-
tion (21).
Continuous infusion of epinephrine per se (day 1) was
associated with a transient activation of the fibrinolytic sys-
tem. Earlier studies demonstrated tPA release after short-
term exposure of humans to epinephrine (5, 6), which
likely reflects a direct effect of epinephrine on the vascular
endothelium (22). Additionally, epinephrine potentiated
the release of tPA in response to injection of LPS. It should
be noted that epinephrine did not cause a general endothe-
lial cell activation, since the release of soluble E-selectin, a
molecule that is shed by the vascular endothelium upon ac-
tivation (14, 23), was inhibited in the EPI-3 and EPI-24
groups. Epinephrine did not influence LPS-induced release
of the main inhibitor of plasminogen activation, PAI-1.
The gradual increase in PAI-1 antigen during infusion of
epinephrine only (day 1) likely reflects a modest acute phase
protein response induced by this hormone, considering that
Figure 3. Epinephrine inhibits LPS-induced soluble E-selectin release.
Mean (6 SE) plasma concentrations of soluble E-selectin after intrave-
nous injection of LPS (2 ng/kg, lot EC-5) at t 5 0. LPS 5 subjects in-
jected with LPS only (n 5 6); EPI-3 5 subjects infused with epinephrine
(30 ng/kg/min) from t 5 23 h to 6 h (n 5 5); EPI-24 5 subjects infused
with epinephrine (30 ng/kg/min) from t 5 224 h to 6 h (n 5 6).  EPI-3
and EPI-24 reduced LPS-induced increases in soluble E-selectin levels
(P ,0.05 versus LPS only).1147 van der Poll et al. Brief Definitive Report
PAI-1 behaves as an acute phase protein during inflamma-
tion (24), and that other acute phase proteins also gradually
increased during epinephrine infusion (data not shown).
Systemic infection and acute injury lead to the activation
of multiple host mediator systems. We demonstrate here
that a physiologically relevant elevation in the plasma levels
of epinephrine markedly influences the activation of hemo-
static mechanism during endotoxemia in humans. The an-
ticoagulant effect of epinephrine represents a property of
this catecholamine not previously recognized that may be
important for the understanding of the complex agonistic
and antagonistic interactions between various mediator sys-
tems involved in the pathogenesis of disseminated intravas-
cular coagulation in acutely ill patients.
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